Literature DB >> 15306549

Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3.

D S Verbeek1, B P van de Warrenburg, P Wesseling, P L Pearson, H P Kremer, R J Sinke.   

Abstract

We report upon a Dutch autosomal dominant cerebellar ataxia (ADCA) family, clinically characterized by a late-onset (>40 years), slowly progressive, isolated spinocerebellar ataxia (SCA). Neuropathological examination in one affected subject showed neuronal loss in the Purkinje cell layer, dentate nuclei and inferior olives, thinning of cerebellopontine tracts, demyelination of posterior and lateral columns in the spinal cord, as well as ubiquitin-positive intranuclear inclusions in nigral neurons that were considered to be Marinesco bodies. Data obtained from the genome-wide linkage analysis revealed a maximal lod score of 3.46 at = 0.00 for marker D20S199. This new SCA locus, on chromosome region 20p13-p12.3, was designated SCA23 after approval by the HUGO Nomenclature Committee. Currently, candidate genes are being screened for mutations within the SCA23 interval. In addition to the recently identified SCA14, SCA19 and FGF14 families, SCA23 is yet another novel SCA locus in the Dutch ADCA population, which further defines the genetic heterogeneity of ADCA families in the Netherlands.

Entities:  

Mesh:

Year:  2004        PMID: 15306549     DOI: 10.1093/brain/awh276

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

1.  Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23.

Authors:  Georgy Bakalkin; Hiroyuki Watanabe; Justyna Jezierska; Cloë Depoorter; Corien Verschuuren-Bemelmans; Igor Bazov; Konstantin A Artemenko; Tatjana Yakovleva; Dennis Dooijes; Bart P C Van de Warrenburg; Roman A Zubarev; Berry Kremer; Pamela E Knapp; Kurt F Hauser; Cisca Wijmenga; Fred Nyberg; Richard J Sinke; Dineke S Verbeek
Journal:  Am J Hum Genet       Date:  2010-10-28       Impact factor: 11.025

Review 2.  Clinical, psychological, and genetic characteristics of spinocerebellar ataxia type 19 (SCA19).

Authors:  H Jurgen Schelhaas; Bart P C van de Warrenburg
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

Review 3.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

Review 4.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

5.  Magnetic resonance imaging in spinocerebellar ataxias.

Authors:  Susanne Döhlinger; Till-Karsten Hauser; Johannes Borkert; Andreas R Luft; Jörg B Schulz
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

6.  The highly heterogeneous spinocerebellar ataxias: from genes to targets for therapeutic intervention.

Authors:  Antoni Matilla-Dueñas
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 7.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

Review 8.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

9.  Spectrum and prevalence of autosomal dominant spinocerebellar ataxia in Hokkaido, the northern island of Japan: a study of 113 Japanese families.

Authors:  Rehana Basri; Ichiro Yabe; Hiroyuki Soma; Hidenao Sasaki
Journal:  J Hum Genet       Date:  2007-09-05       Impact factor: 3.172

10.  Spinocerebellar ataxia type 23: a genetic update.

Authors:  Dineke S Verbeek
Journal:  Cerebellum       Date:  2008-12-17       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.